Guardant Health and Hikma Pharma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

On January 8, 2024, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA). The partnership expands Guardant Health’s global presence and includes products across the cancer care continuum. The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

Login Or Register To Read Full Story